南模生物: 2025年半年度报告摘要

Group 1 - The core viewpoint of the report indicates that Shanghai Southern Model Biotechnology Co., Ltd. has shown a positive trend in its financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year [1][2]. - Total assets at the end of the reporting period amounted to approximately 1.91 billion yuan, reflecting a slight decrease of 1.06% from the previous year [2]. - The net assets attributable to shareholders increased by 0.52% to approximately 1.69 billion yuan compared to the end of the previous year [2]. Group 2 - The company's operating revenue for the reporting period reached approximately 195.76 million yuan, representing a year-on-year increase of 10.69% [2]. - The total profit for the period was approximately 17.57 million yuan, a significant recovery from a loss of approximately 13.13 million yuan in the same period last year [2]. - The net profit attributable to shareholders was approximately 18.17 million yuan, compared to a loss of approximately 9.14 million yuan in the previous year [2]. Group 3 - The net cash flow from operating activities was approximately 3.67 million yuan, a recovery from a negative cash flow of approximately 8.00 million yuan in the same period last year [2]. - The weighted average return on net assets was 1.08%, a recovery from -0.53% in the previous year [2]. - Basic and diluted earnings per share were both 0.23 yuan, compared to -0.12 yuan in the previous year [2]. Group 4 - The proportion of research and development investment to operating revenue was 21.24%, a slight decrease of 0.7 percentage points from the previous year [2]. - The total number of shareholders at the end of the reporting period was 6,522 [2].